Producing Recombinant Adeno-Associated Virus in Foster Cells: Overcoming Production Limitations Using a Baculovirus–Insect Cell Expression Strategy
- 1 August 2009
- journal article
- review article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 20 (8), 807-817
- https://doi.org/10.1089/hum.2009.092
Abstract
Establishing pharmacological parameters, such as efficacy, routes of administration, and toxicity, for recombinant adeno-associated virus (rAAV) vectors is a prerequisite for gaining acceptance for clinical applications. In fact, even a therapeutic window, that is, the dose range between therapeutic efficacy and toxicity, has yet to be determined for rAAV in vivo. Multiphase clinical trials investigating the safety and efficacy of recombinant AAV-based therapeutics will require unprecedented vector production capacity to meet the needs of preclinical toxicology studies, and the progressive clinical protocol phases of safety/dose escalation (phase I), efficacy (phase II), and high-enrollment, multicenter evaluations (phase III). Methods of rAAV production capable of supporting such trials must be scalable, robust, and efficient. We have taken advantage of the ease of scalability of nonadherent cell culture techniques coupled with the inherent efficiency of viral infection to develop an rAAV production method based on recombinant baculovirus-mediated expression of AAV components in insect-derived suspension cells.Keywords
This publication has 72 references indexed in Scilit:
- A Simplified Baculovirus-AAV Expression Vector System Coupled With One-step Affinity Purification Yields High-titer rAAV Stocks From Insect CellsMolecular Therapy, 2009
- Transient Transfection Methods for Clinical Adeno-Associated Viral Vector ProductionHuman Gene Therapy, 2009
- An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Production of recombinant adeno-associated vectors using two bioreactor configurations at different scalesJournal of Virological Methods, 2007
- Development and characterization of a cell line for large‐scale, serum‐free production of recombinant adeno‐associated viral vectorsThe Journal of Gene Medicine, 2004
- Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybridsGene Therapy, 2004
- High-Titer Recombinant Adeno-Associated Virus Production from Replicating Amplicons and Herpes Vectors Deleted for Glycoprotein HHuman Gene Therapy, 1999
- High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and CapGene Therapy, 1999
- Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirusGene Therapy, 1999
- Cell Lines for the Production of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1995